The Effect of Growth Hormone Replacement on Liver Fat

Status Completed

Clinical Trial Summary

We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the liver.

To compare the results we will include growth hormone deficient patients who do not start GH replacement as controls.

Clinical Trial Description

Adults with untreated growth hormone deficiency (GHD), a condition mostly due to pituitary disease, often show metabolic features similar to those described in the 'metabolic syndrome'. Growth hormone (GH) replacement has been shown to reverse many of these unfavorable changes, with a particular evident reduction of visceral fat. In recent years, a strong correlation between fat accumulation in the liver and features of the metabolic syndrome (particularly visceral fat) has been identified, and 'fatty liver' is now being referred as the hepatic feature of the 'metabolic syndrome'. The effect of GH replacement on liver fat, however, has never been systematically studied.

We will assess 15 patients with GHD before and 6 months after starting GH replacement. We will also assess 15 control patients with GHD but who don't go on GH replacement for various reasons.

Liver fat will be assessed using MR spectroscopy. Changes in liver fat will be correlated to changes in insulin sensitivity and changes in various inflammatory markers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00774579
Study type	Observational
Source	Imperial College London
Contact
Status	Completed
Phase
Start date	March 2008
Completion date	October 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Recruiting	`NCT06051669` - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting	`NCT05984745` - Effect of CoQ10 on the Outcome of MAFLD Patients	Phase 2
Completed	`NCT02565446` - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram	N/A
Not yet recruiting	`NCT01694342` - Telomere Parameters in Patients With Nonalcoholic Fatty Liver	N/A
Completed	`NCT01464801` - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease	N/A
Completed	`NCT01992809` - Omega 3 Supplementation in Fatty Liver	Phase 3
Completed	`NCT00244569` - Development of a Breath Test for Monitoring Patients With Liver Disease	Phase 3
Completed	`NCT00063635` - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)	Phase 3
Recruiting	`NCT03972319` - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study	Early Phase 1
Completed	`NCT03141008` - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Recruiting	`NCT05125757` - Lifestyle Modification in Psoriatic Patients With Fatty Liver	N/A
Recruiting	`NCT05370053` - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology	N/A
Recruiting	`NCT04371042` - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed	`NCT04004273` - Diabetes, Exercise and Liver Fat (DELIVER)	N/A
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting	`NCT02265276` - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease	Phase 3
Completed	`NCT02347007` - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults	N/A
Completed	`NCT01934777` - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis	Phase 3